tiprankstipranks
Advertisement
Advertisement

RIGL Stock Latest News

Lilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches Completion
Company AnnouncementsLilly and Rigel Advance RA Pipeline as Key LY3871801 Mid-Stage Trial Reaches Completion
4d ago
LLY
RIGL
Rigel: Buy Rating Reiterated as New Oncology Data Support Franchise Strength and Unchanged $57 Price Target
PremiumRatings
Rigel: Buy Rating Reiterated as New Oncology Data Support Franchise Strength and Unchanged $57 Price Target
5d ago
RIGL
Rigel Shareholders Approve Equity Plans and Board Slate
PremiumCompany Announcements
Rigel Shareholders Approve Equity Plans and Board Slate
6d ago
8K
RIGL
Rigel Pharmaceuticals Highlights Growth Amid Rising Costs
PremiumCompany Announcements
Rigel Pharmaceuticals Highlights Growth Amid Rising Costs
7d ago
RIGL
Arvinas price target raised to $16 from $14 at BofA
PremiumThe Fly
Arvinas price target raised to $16 from $14 at BofA
13d ago
PFE
ARVN
Arvinas price target raised to $18 from $16 at BTIG
PremiumThe FlyArvinas price target raised to $18 from $16 at BTIG
14d ago
ARVN
RIGL
Rigel Pharmaceuticals price target raised to $81 from $69 at Citi
Premium
The Fly
Rigel Pharmaceuticals price target raised to $81 from $69 at Citi
14d ago
RIGL
Rigel Secures Global Rights to VEPPANU Breast Cancer Therapy
Premium
Company Announcements
Rigel Secures Global Rights to VEPPANU Breast Cancer Therapy
14d ago
8K
RIGL
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
PremiumThe Fly
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
14d ago
PFE
ARVN
Analyst Reiterates Buy on Rigel as VEPPANU Acquisition Expands Portfolio; Price Target Maintained at $57
PremiumRatings
Analyst Reiterates Buy on Rigel as VEPPANU Acquisition Expands Portfolio; Price Target Maintained at $57
14d ago
RIGL
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
PremiumThe Fly
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
14d ago
PFE
ARVN
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer
PremiumThe Fly
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer
15d ago
PFE
ARVN
Rigel Pharmaceuticals price target lowered to $69 from $71 at Citi
PremiumThe FlyRigel Pharmaceuticals price target lowered to $69 from $71 at Citi
20d ago
RIGL
Rigel Pharmaceuticals Signals Profitable Growth After Earnings Call
Premium
Company Announcements
Rigel Pharmaceuticals Signals Profitable Growth After Earnings Call
20d ago
RIGL
Rigel Pharmaceuticals reports Q1 EPS 44c, consensus 87c
Premium
The Fly
Rigel Pharmaceuticals reports Q1 EPS 44c, consensus 87c
21d ago
RIGL
Rigel Pharma reaffirms FY26 revenue view $275M-$290M, consensus $284.07M
PremiumThe Fly
Rigel Pharma reaffirms FY26 revenue view $275M-$290M, consensus $284.07M
21d ago
RIGL
Is RIGL a Buy, Before Earnings?
PremiumPre-Earnings
Is RIGL a Buy, Before Earnings?
24d ago
RIGL
Rigel: Core Growth Thesis Intact Despite Eli Lilly’s R552 Exit, With Commercial Portfolio and R289 Pipeline Driving Buy Rating
PremiumRatings
Rigel: Core Growth Thesis Intact Despite Eli Lilly’s R552 Exit, With Commercial Portfolio and R289 Pipeline Driving Buy Rating
1M ago
RIGL
Rigel Regains Rights as Eli Lilly Ends Collaboration
PremiumCompany Announcements
Rigel Regains Rights as Eli Lilly Ends Collaboration
1M ago
8K
RIGL
Rigel Pharmaceuticals Balances Breakout Growth With Caution
PremiumCompany AnnouncementsRigel Pharmaceuticals Balances Breakout Growth With Caution
2M ago
RIGL
Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial
Premium
The Fly
Rigel Pharmaceuticals’ pralsetinib shows efficacy in NSCLC clinical trial
2M ago
RIGL
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors
Premium
Company Announcements
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors
2M ago
RIGL

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >